Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition
Boston Scientific Corporation (NYSE: BSX), a leading player in the medical device industry, has announced...
Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases
Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...
Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong
Peijia Medical Ltd (HKG: 9996), a leading medical device company, has announced the completion of...
Sanofi’s Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review
French pharmaceutical giant Sanofi has announced that the US Food and Drug Administration (FDA) has...
Novo Nordisk Launches Semaglutide for Weight Management in China
Denmark-based healthcare giant Novo Nordisk A/S (NYSE: NVO) has announced the official market launch of...
Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a leading biopharmaceutical company based in China, has...
Exegenesis Bio’s Gene Therapy EXG110 Earns Orphan Drug Status for Fabry Disease
Exegenesis Bio, a leading provider of epigenetics experimental and analytical services headquartered in Hangzhou, has...
Shenzhen Weiguang Biological Partners with SUAT to Boost Life Science and Health Industry
Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a prominent blood products manufacturer in China,...
Janssen-Cilag’s Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment
Janssen-Cilag International NV, a subsidiary of the US pharmaceutical giant Johnson & Johnson (J&J; NYSE:...
Shanghai Junshi Biosciences’ Toripalimab Wins UK Approval for Nasopharyngeal and Oesophageal Cancers
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
C-Ray Therapeutics Secures Over $100 Million in Series A+ Financing for Radiopharmaceuticals
C-Ray Therapeutics, a specialist in radiopharmaceuticals headquartered in Chengdu, has announced the successful completion of...
BioNTech Acquires Biotheus for $800 Million, Enhancing Oncology Pipeline
BioNTech (NASDAQ: BNTX), the biotech giant recognized for its role in developing the COVID-19 vaccine,...
Suzhou Ribo Life Science Receives EU Approval for Phase II Trial of RBD5044
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB have announced that...
Ascentage Pharma Submits Application for Lisaftoclax, a Novel Oral Bcl-2 Inhibitor
Ascentage Pharma (HKG: 6855) has announced that its proprietary oral Bcl-2 selective inhibitor, Lisaftoclax (APG-2575),...
C-Ray Therapeutics Secures Over $100 Million in A+ Round Financing
C-Ray Therapeutics (Chengdu) Co., Ltd., an innovative enterprise in the field of radioactive medicines, has...
Bliss Bio Secures NMPA Approval for BB-1712, Pioneering ADC Therapy
Bliss Bio announced that its Investigational New Drug (IND) application for the innovative antibody-drug conjugate...
Merck KGaA Reports 3.8% Organic Growth in Q3 2024 Financials
Merck KGaA (NYSE: MRK), the German multinational science and technology company, has released its financial...
Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization
China-based biopharmaceutical company Impact Therapeutics has reportedly secured RMB 250 million (USD 34.5 million) in...
GSK’s Blenrep Shows Survival Benefit in Phase III Multiple Myeloma Study
UK-based pharmaceutical company GSK plc (NYSE: GSK) has reported positive results from a Phase III...
Janssen-Cilag’s Nipocalimab Shows Promise in Phase II Study for Sjögren’s Disease
Janssen-Cilag International NV, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), has unveiled the...